Lenz Therapeutics (LENZ) announced VIZZ 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults, is now available. Professional product sample distribution by the sales force to optometrists and ophthalmologists has been initiated nationwide. Commercial product shipments will be initiated to consumers in October through our ePharmacy partner and is anticipated to be broadly available, including via retail pharmacies, by mid-Q4 2025.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LENZ:
- Strong Buy Recommendation for LENZ Therapeutics: Early Approval and Strategic Launch of VIZZ Eye Drops
- Lenz Therapeutics price target raised to $53 from $44 at BofA
- Lenz Therapeutics price target raised to $56 from $48 at H.C. Wainwright
- Buy Rating for LENZ Therapeutics: Vizz’s Early FDA Approval and Market Differentiation Drive Growth Potential
- Lenz Therapeutics price target raised to $52 from $49 at Citi